Background Patients with advanced multiple myeloma (stage III or progressive myeloma) received the CAD protocol every three weeks cyclophosphamide 200 mg/m 2 l v /orally days 1-4, adriamycin 30 mg/m 2 l v on day 1 and dexamethasone 40 mg p o days 1-4
Introduction
Since its introduction in 1969, when Alexanian [1] described the combination of melphalane and prednisone (MP) to be effective in the treatment of multiple myeloma (MM), this regimen is regarded as the palliative 'gold standard'. The MP protocol induces approximately 40%-50% responses with a median survival between 19 and 39 months. A variety of different chemotherapy regimens, either mono-or polychemotherapy have been tested for the treatment of this disease since [2] Mainly, three cytotoxic agents were shown to be effective either as single compounds or in combination chemotherapy [3] [4] [5] : dexamethasone, alkylating agents (melphalane, cyclophosphamide) and adriamycin. Dexamethasone alone induces remissions in 40%-50% of the patients [6] . Cyclophosphamide, being as effective as melphalane [7] , produces around 25% of remissions in myeloma patients [5, 8] . Finally, adriamycin given in combination regimens is associated with a remission rate of up to 50% [9] .
Here we report a phase II study of a combination of the three main active drug groups in MM, namely the CAD protocol: cyclophosphamide, adriamycin and dexamethasone.
Patients and methods

Patients
Between July 1995 and May 1999 all consecutive patients with MM were offered enrolment into the study if they met the following criteria histologicaly proven MM. stage III disease according to SalmonDune irrespectively of renal involvement or stage II with progressive monoclonal protein, Karnofsky score >60%, adequate hjematological and organ function (leukocyte count > 2000/ul, platelet count >50,000/ul, except lower levels due to myeloma infiltration of bone marrow, SGOT, SGPT, alkaline phosphdtase, bilirubin <2 times upper limit) Main exclusion criteria were hemodialysis and severe cardiac disease (>NYHA 11) Pre-treatment evaluation included a complete medical history, physical examination including performance status and vital signs, bone marrow aspirate and biopsy, electrophoresis and immunofixation of serum or urine, complete blood count including differential and platelets, ESR, LDH, p2-microglobulin, CRP, routine serum chemistry parameters to assess renal and hepatic function. ECG, and a chest X-ray
Treatment
The treatment regimen consisted of cyclophosphamide 200 mg/m 2 p o or l v day 1-4, adriamycin 30 mg/m 2 I v on day I and dexamethasone 40 mg po day 1-4 (CAD) Treatment was repeated every three weeks Treatment was stopped in case of complete remission, in case of no further reduction in monoclonal-protein or in case of progressive disease Patients scheduled for high dose chemotherapy received four cycles of CAD Treatment was mostly given in an outpatient setting In case of grade 3 or 4 leuko-or thrombocytopenia further treatment was postponed until resolution
The protocol had been approved by the local ethics committee Prior to study entry, written informed consent was obtained from every patient
Responses
Responses were classified according to the criteria of the EBMT-IBMT-ABMT [10] Complete response was defined as complete disappearance of monoclonal protein (m-protein) in immunofixation for at least six weeks, a bone marrow infiltration by plasma cells of < 5% and no increase in size or number of osteolytic lesions For partial response a reduction of more than 50% of the pre-treatment value of the m-protein for at least six weeks or a reduction of > 90% in urinary light chain excretion and no increase in size or number of osteolytic lesions was required Minimal response was defined as a reduction of more than 25% of the pre-treatment value of the m-protein for at least six weeks or a reduction of > 50% in urinary light chain excretion and no increase in size or number of osteolytic lesions Progressive disease was defined as an increase of more than 25% of the pre-treatment value of the monoclonal protein or in urinary light chain excretion, hypercalcacmia not attributable to any other cause or an increase in size or number of osteolytic lesions Any other state was classified as no change
Time to progression was defined as time from reaching objective remission to progression Survival time was defined as time from start of study entry to death
Monitoring, loxicity
For monitoring the disease status of myeloma electrophoresis and immunofixdtion of serum or urine were performed before start of therapy, after every second cycle, and after end of treatment Evaluation of toxicity, classified according to the criteria of the WHO [II] included physical examination prior to every cycle of therapy, a complete blood cell counts and serum assessment of renal and hepatic function In case of complete disappearance of m-protein bone marrow aspirate was repealed Each patient after having at least one dose of protocol therapy, was evaludble for toxicity Each patient with more than two cycles was evaluated for efficacy Analysis was performed on an intent to treat basis (Table 1) Since July 1995 46 patients were treated: 13 female and 33 male. Median age was 60 years (range 34-84 years) Myeloma subtypes were. IgG 28 patients, IgA 11 patients, IgM 2 patients, light chain disease 5 patients. According to Dune-Salmon 44 patients were stage III, 2 stage II and 6 patients had stage B (renal insufficiency). Plasmoblastic disease was found in three patients. The median level of p2-microglobulin was 2 6 mg/dl (range 1 1-5.6 mg/dl). Of 46 patients 21 had relapsing disease after chemotherapy with MP, three patients relapsed after additional VAD and one patient after high-dose chemotherapy. In seven patients more than one chemotherapy regimen had been given prior to study entry.
Results
Patient characteristics
A total of 209 cycles have been administered with a median of 4 cycles per patient (range 1-7 cycles) 
21 (46) 14 7 63 45-84
13 (62) 6 (30) 1 (4) 1 (4) 20 (96) 1 (4) 4 (16) 30 5 (24) 21(100) 3 (14) 1 (4) 7 (33) 35 8-240
Range 11-56
Toxicity
All patients were evaluated for toxicity. Myelosuppression and consecutive febrile episodes was the predominant toxicity Leukopenia or thrombocytopenia grade 3 or 4 was observed in 18% and 6% of all treatment cycles, respectively. Febrile neutropenia occurred in 11% of cycles with one fatal outcome. Another patient died due to infection in week 4 after the last chemotherapy. Four patients presented with pneumonia, one patient with meningitis during chemotherapy. Two patients died due to progressive disease after one and three cycles of CAD, respectively. Other side effects like nausea, hair loss and gastrointestinal toxicity were mild (WHO grade 2 or less).
Response
Responses rates for the patients are given in Table 2 . The objective response rate (OR = complete and partial response) was 74% for the whole study population.
Since patients numbers are to small subgroup analysis has only descriptive value. CAD is slightly more effective in newly diagnosed patients than in relapsed patients (OR 80% vs. 67%). The subgroup of patients intended to be treated with high dose chemotherapy (HDT) had the best response rate (OR 85%). Four of the six patients with renal insufficiency showed a partial response, lasting (67) 14 (67) 3 (14) 3 (14) K5) 55 17-80 0 between three and twenty-one months. In patients relapsing after MP, response rate was high, irrespective whether patients initially responded to MP (11 patients, OR 72%) or were progressive to initial MP (10 patients, OR 60%). All three patients treated with CAD after VAD (4, 6 and 20 months after last VAD) reached PR. Two patients relapsing eight and twelve months after CAD were effectively retreated with CAD.
Stem-cell mobilisation
After completing 4 cycles of CAD, 15 patients entered an autologous stem-cell mobilisation protocol with cyclophosphamide 4 g and G-CSF 5 ug/kg. In all 15 patients a median of 3.5 x 10 6 CD34+ cells/kg could be harvested on days 11-13 suggesting that pretreatment with CAD did not impair the stem-cell pool Thirteen of the later patients were treated with HDT.
Progression-free interval/survival
Survival and time to progression was calculated for the 33 patients without subsequent HDT.
Of the 23 patients having reached an objective remission, 8 patients relapsed after a median of 10 months (range 3-23 months). With 17 patients still alive, median survival was also not reached after a median follow-up of 14 months (range 4-50 months). Figure 1 shows a Kaplan-Meier plot for time to progression.
Discussion
Over the past thirty years, several chemotherapy regimens have been tested for treatment of multiple myeloma. However MP (melphalane, prednisone) remained the standard palliative therapy for advanced myeloma. Unfortunately, only a minority (30%-40%) of patients achieve an objective response with a short duration of less than one year (reviewed in [3, 5] proved to be more effective with response rates as high as 50%-84%. However, in the early VAD studies only a minority of patients were in advanced stages II and III [13, 14] and subsequent studies showed no major benefit in terms of survival [13, 14] Adding infusional vincristin to the combination therapy is associated with toxicity and the therapeutic value is small [5] . Other multidrug protocols such as VMBCP [15] , ABCM [16] or alternating VMCP-VBAP [17] were found to have substantial efficacy in selected patients, but not for the whole group of myeloma patients.
This study was designed to evaluate a combination of cytotoxic drugs with proven efficacy in the treatment of myeloma. This combination has been tested previously [18] , but the dosages applied were relatively low (adriamycin 25 mg/m 2 on day 1, cyclophosphamide 100 mg/m 2 and prednisone 60 mg/m 2 days 1-4) resulting in a remission rate of only 39%. Therefore we combined the same compounds in higher dosages in this study: cyclophosphamide 200 mg/m 2 p.o. or I.V. days 1-4, adriamycin 30 mg/m 2 i.v. on day 1 and dexamethasone 40 mg p.o. days 1-4 for the so-called CAD regimen.
The data of our study shows high efficacy of this combination in patients with advanced multiple myeloma In newly diagnosed patients, an objective response rate (OR = partial and complete responses) of 80% was observed In patients relapsing after MP, response rate was high, irrespective whether patients initially responded to initial MP (11 patients, OR 72%) or were progressive to MP (10 patients, OR 60%). Also all anthracycline (VAD) pre-treated patients reached an OR Out of 6 patients with renal insufficiency four reached a partial response. The two patients having relapsed after 6 and 10 months after CAD were again successfully treated with CAD.
The objective remission rate achieved with CAD in our study population is in the upper part of published phase II and III data reported for VAD, VMBCP. ABCM or VMCP-VBAP [2, 5, [15] [16] [17] 19] . Since reaching CR might be of most importance for long-time survival in myeloma CAD with a CR rate of only 4% per se is only palliative.
Stem-cell mobilisation in each out of 15 patients was good. Thus, CAD seems to be also a suitable pretransplant regimen for high-dose chemotherapy programme combining good efficacy with rather low stem-cell toxicity CAD is a well tolerated chemotherapy regimen which can be given on an outpatient basis. Main toxicity was myelosuppression However, one fatal infection occurred in patients presenting with progressive septicaemia to our clinic after having two days of neutropenic fever. Severe thrombocytopenia did not compromise the treatment if treatment intervals were prolonged to four weeks. It remains unclear whether the high frequency of pneumonia (4 patients) is due to CAD or myeloma itself.
In comparison to the widely used VAD there are several considerations in favour of CAD. VAD may be complicated by side effects either through the need for a central venous line or the prolonged administration of dexamethasone. The prevalence of catheter related sepsis and thrombosis has been documented in up to 25% of patients receiving VAD [13] and attempts to administer VAD on an outpatient basis were associated with considerable complications [20] . Prolonged infusion of vincnstin is associated with an increased rate of sensory polyneuropathy and paralytic ileus [21] . Side effects of prolonged dexamethasone therapy such as peptic ulcer disease, diabetes, psychosis and promotion of osteoporosis have to be considered as well.
After a median follow-up of 14 months median survival time is not reached in this study. However, clinical trials have shown that a high remission rate of more than 70% may translate into improved survival [22] . As MP is the only chemotherapy regimen besides high-dose chemotherapy proven to be of survival benefit the effect of CAD on progression-free and overall survival has to be tested in a comparative trial against MP.
Treatment of multiple myeloma still is palliative. Therefore new therapies should be effective in reducing the m-protein without significant side effect, given on an outpatient basis. They should not impair stem cell to keep the option of high-dose chemotherapy with autologous stem-cell support.
In conclusion, CAD is an active treatment regimen in the treatment of MM. Because of its low toxicity profile it is a suitable protocol for outpatient treatment Prospective, randomised trials are warranted to evaluate the effects of CAD on survival
